Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy
Hypertension; Hypertrophy, Left Ventricular
About this trial
This is an interventional treatment trial for Hypertension; Hypertrophy, Left Ventricular focused on measuring Left ventricular hypertrophy, hypertension, valsartan, amlodipine
Eligibility Criteria
Inclusion Criteria:
- Caucasian; male or female outpatients and age between 18-80 years of age, inclusive.
- Patients with a history of essential hypertension and who are actually treated either with an antihypertensive monotherapy and with a diastolic blood pressure >=90 and <= 105mmHg or with a combination therapy (limited to two active compounds) and with a diastolic blood pressure of >=90 and <= 100mmHg.
- Patients with Left Ventricular Hypertrophy
Exclusion Criteria:
- Severe hypertension
- Symptomatic heart failure
- History of stroke, heart attack, coronary bypass surgery etc.
- Insulin-dependent diabetes mellitus or poorly controlled diabetes mellitus.
Other protocol-defined inclusion/exclusion criteria may apply
Sites / Locations
- 25 centers in Germany
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Amlodipine + Valsartan
Losartan + Hydrochlorothiazide
Participants received 160 mg Valsartan and 5 mg amlodipine orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to valsartan/amlodipine 160/10 mg. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication.
Participants received 100 mg losartan and 12.5 mg Hydrochlorothiazide (HCT) orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to losartan/HCT 100/25 mg, respectively, until end of study. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication.